Troels Bygum Knudsen1, Gideon Ertner1, Janne Petersen2, Holger Jon Møller3, Søren K Moestrup4, Jesper Eugen-Olsen5, Gitte Kronborg6, Thomas Benfield7. 1. Department of Infectious Diseases. 2. Optimed, Clinical Research Center Section of Biostatistics, Department of Public Health. 3. Department of Clinical Biochemistry, Aarhus University Hospital. 4. Department of Biomedicine, Aarhus University Institute of Molecular Medicine, University of Southern Denmark, Odense. 5. Clinical Research Center, Hvidovre Hospital. 6. Department of Infectious Diseases Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen. 7. Department of Infectious Diseases Clinical Research Center, Hvidovre Hospital Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen.
Abstract
BACKGROUND: CD163, a monocyte- and macrophage-specific scavenger receptor, is shed as soluble CD163 (sCD163) during the proinflammatory response. Here, we assessed the association between plasma sCD163 levels and progression to AIDS and all-cause mortality among individuals infected with human immunodeficiency virus type 1 (HIV). METHODS: Plasma sCD163 levels were measured in 933 HIV-infected individuals. Hazard ratios (HRs) with 95% confidence intervals (CIs) associated with mortality were computed by Cox proportional hazards regression. RESULTS: At baseline, 86% were receiving antiretroviral treatment, 73% had plasma a HIV RNA level of <50 copies/mL, and the median CD4(+) T-cell count was 503 cells/µL. During 10.5 years of follow-up, 167 (17.9%) died. Plasma sCD163 levels were higher in nonsurvivors than in survivors (4.92 mg/L [interquartile range {IQR}, 3.29-8.65 mg/L] vs 3.16 mg/L [IQR, 2.16-4.64 mg/L]; P = .0001). The cumulative incidence of death increased with increasing plasma sCD163 levels, corresponding to a 6% or 35% increased risk of death for each milligram per liter or quartile increase, respectively, in baseline plasma sCD163 level (adjusted HR, 1.06 [95% CI, 1.03-1.09] and 1.35 [95% CI, 1.13-1.63], respectively). CONCLUSIONS: Plasma sCD163 was an independent marker of all-cause mortality in a cohort of HIV-infected individuals, suggesting that monocyte/macrophage activation may play a role in HIV pathogenesis and be a target of intervention.
BACKGROUND:CD163, a monocyte- and macrophage-specific scavenger receptor, is shed as soluble CD163 (sCD163) during the proinflammatory response. Here, we assessed the association between plasma sCD163 levels and progression to AIDS and all-cause mortality among individuals infected with human immunodeficiency virus type 1 (HIV). METHODS: Plasma sCD163 levels were measured in 933 HIV-infected individuals. Hazard ratios (HRs) with 95% confidence intervals (CIs) associated with mortality were computed by Cox proportional hazards regression. RESULTS: At baseline, 86% were receiving antiretroviral treatment, 73% had plasma a HIV RNA level of <50 copies/mL, and the median CD4(+) T-cell count was 503 cells/µL. During 10.5 years of follow-up, 167 (17.9%) died. Plasma sCD163 levels were higher in nonsurvivors than in survivors (4.92 mg/L [interquartile range {IQR}, 3.29-8.65 mg/L] vs 3.16 mg/L [IQR, 2.16-4.64 mg/L]; P = .0001). The cumulative incidence of death increased with increasing plasma sCD163 levels, corresponding to a 6% or 35% increased risk of death for each milligram per liter or quartile increase, respectively, in baseline plasma sCD163 level (adjusted HR, 1.06 [95% CI, 1.03-1.09] and 1.35 [95% CI, 1.13-1.63], respectively). CONCLUSIONS: Plasma sCD163 was an independent marker of all-cause mortality in a cohort of HIV-infected individuals, suggesting that monocyte/macrophage activation may play a role in HIV pathogenesis and be a target of intervention.
Authors: Michael Reid; Yifei Ma; Rebecca Scherzer; Jennifer C Price; Audrey L French; Michael W Plankey; Carl Grunfeld; Phyllis C Tien Journal: AIDS Date: 2017-01-28 Impact factor: 4.177
Authors: Lindsay T Fourman; Natalia Czerwonka; Sofia D Shaikh; Takara L Stanley; Tricia H Burdo; Kenneth C Williams; Kathleen V Fitch; Janet Lo; Steven K Grinspoon Journal: AIDS Date: 2018-04-24 Impact factor: 4.177
Authors: Michael J A Reid; Yifei Ma; Iya Golovaty; Samson Okello; Ruth Sentongo; Maggie Feng; Alexander C Tsai; Bernard Kakuhikire; Russell Tracy; Peter W Hunt; Mark Siedner; Phyllis C Tien Journal: AIDS Patient Care STDS Date: 2019-06-12 Impact factor: 5.078
Authors: Leila B Giron; Florent Colomb; Emmanouil Papasavvas; Livio Azzoni; Xiangfan Yin; Matthew Fair; Alitzel Anzurez; Mohammad Damra; Karam Mounzer; Jay R Kostman; Pablo Tebas; Una O'Doherty; Hiroaki Tateno; Qin Liu; Michael R Betts; Luis J Montaner; Mohamed Abdel-Mohsen Journal: EBioMedicine Date: 2020-08-19 Impact factor: 8.143
Authors: Arcadio Agudelo-Hernandez; Yue Chen; Arlene Bullotta; William G Buchanan; Cynthia R Klamar-Blain; Luann Borowski; Sharon A Riddler; Charles R Rinaldo; Bernard J C Macatangay Journal: AIDS Date: 2017-09-24 Impact factor: 4.177
Authors: Amy C Justice; Kristine M Erlandson; Peter W Hunt; Alan Landay; Paolo Miotti; Russell P Tracy Journal: J Infect Dis Date: 2018-01-30 Impact factor: 5.226